What is Prescient Therapeutics Limited's (PTX.AX) StockRank?

MoatMap's StockRank for Prescient Therapeutics Limited (PTX.AX) is 17/100, with a Strong Sell signal. This is a composite score combining Quality (40), Value (25), and Momentum (36) factor ranks across MoatMap's 20,000+ stock universe.

Does Prescient Therapeutics Limited have an economic moat?

Prescient Therapeutics Limited (PTX.AX) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Prescient Therapeutics Limited a buy, hold, or sell?

MoatMap's current signal for Prescient Therapeutics Limited (PTX.AX) is Strong Sell, based on a StockRank of 17/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Prescient Therapeutics Limited in?

Prescient Therapeutics Limited (PTX.AX) operates in the Healthcare sector, specifically the Biotechnology industry (Australia).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

PTX.AX

STRONG SELLREMOVE

Prescient Therapeutics Limited · Healthcare · Australia · $59M · Avg Vol: $45K/d

StockRank

P/E (TTM)

—

ROE

-54.3%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Prescient Therapeutics is an early-stage clinical biotech company with binary trial risks and no current revenues, failing our requirement for high-ROIC, established business models.

COMPANY DESCRIPTION

Prescient Therapeutics Limited is an Australian clinical-stage oncology biotechnology company developing novel, personalized cancer therapies. The company's pipeline includes targeted small molecules and next-generation CAR-T cell therapies designed to overcome the limitations of current immunotherapies. Prescient's competitive advantage is its proprietary OmniCAR platform, which enables controllable, multi-armed, and redirectable cellular immunotherapies.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	—	—	—	—	—
EPS	—	-0.01	-0.01	-0.01	-0.01	—
Shares	—	654.3M	805.3M	805.3M	805.3M	+23.1%
Debt	0.1M	0.6M	1.4M	0.2M	2.2M	109.2%
Equity	—	11.7M	18.3M	12.7M	8.0M	-12.1%
Op CF	—	—	—	—	—	—
Inv CF	—	-3,101	-11.2M	8.4M	2.8M	—
Fin CF	—	0.3M	11.1M	12,709	-0.2M	—

PRICE (1Y)+25.9%

SMA 50SMA 200

$0.05

RSI (14)

35.3

52W High

$0.09

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

-104.4%5.1

ROE

-54.3%16.3

GP/Assets

29.5%64.6

Op. Margin

-344.0%11.5

FCF/Assets

-33.1%7.9

Piotroski

239.0

Int. Cover

—N/A

D/E Ratio

0.02x84.9

Current Ratio

12.95x91.0

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

4.4x29.4

P/S

17.5x18.7

Div Yield

—N/A

Momentum

52W High %

54%31.2

RS 6M

-38%31.9

SMA 50/200

1.01x66.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$59M

P/E (Forward)

7.1x

Gross Margin

100.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PTX.AX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
PTX.AX	Prescient Therapeutics Limited(you)	$59M	17	STRONG SELL
ATX.AX	Amplia Therapeutics Limited	$56M	15	STRONG SELL
LTP.AX	LTR PHARMA FPO [LTP]	$71M	19	STRONG SELL
BOT.AX	Botanix Pharmaceuticals Limited	$51M	9	STRONG SELL
IMM.AX	Immutep Limited	$54M	6	STRONG SELL
ACW.AX	Actinogen Medical Limited	$87M	8	STRONG SELL
ILA.AX	Island Pharmaceuticals Limited	$76M	5	STRONG SELL
PAR.AX	Paradigm Biopharmaceuticals Limited	$70M	0	STRONG SELL
OCC.AX	Orthocell Limited	$146M	14	STRONG SELL
NYR.AX	Nyrada Inc.	$79M	1	STRONG SELL

Peer medians: ROE -19.4% · P/E 22.4x · Gross margin 49.7%

Prescient Therapeutics Limited (PTX.AX) — Stock Score Summary

Prescient Therapeutics Limited (PTX.AX) has a MoatMap StockRank of 17/100 based on Quality (40/100), Value (25/100), and Momentum (36/100) factor scores. The current signal is STRONG SELL. Prescient Therapeutics is an early-stage clinical biotech company with binary trial risks and no current revenues, failing our requirement for high-ROIC, established business models.

Key Financial Metrics

Price	$0.05
Market Cap	$59M
P/E (Forward)	7.10
Price/Book	4.44
Return on Equity	-54.3%
Return on Invested Capital	-104.4%
Debt/Equity	1.61
Gross Margin	100.0%
Operating Margin	-344.0%
Revenue Growth	-7.3%
Free Cash Flow	$-3M

Prescient Therapeutics Limited operates in the Biotechnology industry, part of the Healthcare sector (Australia).

Frequently Asked Questions

What is Prescient Therapeutics Limited’s (PTX.AX) StockRank?: MoatMap’s StockRank for Prescient Therapeutics Limited (PTX.AX) is 17/100, with a Strong Sell signal. It is a composite of Quality (40), Value (25), and Momentum (36) factor ranks across MoatMap’s 20,000+ stock universe.
Does Prescient Therapeutics Limited have an economic moat?: Prescient Therapeutics Limited (PTX.AX) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Prescient Therapeutics Limited a buy, hold, or sell?: MoatMap’s current signal for Prescient Therapeutics Limited (PTX.AX) is Strong Sell, based on a StockRank of 17/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Prescient Therapeutics Limited in?: Prescient Therapeutics Limited (PTX.AX) operates in the Healthcare sector, specifically the Biotechnology industry (Australia).